This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Capon F. The genetic basis of psoriasis. Int J Mol Sci. 2017; 18: 2526.CaponFThe genetic basis of psoriasisInt J Mol Sci201718252610.3390/ijms18122526575112929186830Search in Google Scholar
Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004; 135: 1–8.GudjonssonJEJohnstonASigmundsdottirHValdimarssonHImmunopathogenic mechanisms in psoriasisClin Exp Immunol20041351810.1111/j.1365-2249.2004.02310.x180892814678257Search in Google Scholar
Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018; 178: 854–862.ChenLTsaiTFHLA-Cw6 and psoriasisBr J Dermatol201817885486210.1111/bjd.16514Search in Google Scholar
Murphy EC, Nussbaum D, Prussick R, Friedman AJ. Use of complementary and alternative medicine by patients with psoriasis. J Am Acad Dermatol. 2019; 81: 280–283.MurphyECNussbaumDPrussickRFriedmanAJUse of complementary and alternative medicine by patients with psoriasisJ Am Acad Dermatol20198128028310.1016/j.jaad.2019.03.05930935988Search in Google Scholar
Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. Br J Dermatol. 2013; 168: 1303–1310.DanielsenKOlsenAOWilsgaardTFurbergASIs the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohortBr J Dermatol20131681303131010.1111/bjd.1223023374051Search in Google Scholar
Kunz M, Simon JC, Saalbach A. Psoriasis: Obesity and fatty acids. Front Immunol. 2019; 10: 1807.KunzMSimonJCSaalbachAPsoriasis: Obesity and fatty acidsFront Immunol201910180710.3389/fimmu.2019.01807668494431417571Search in Google Scholar
Owczarczyk-Saczonek A, Placek W. Compounds of psoriasis with obesity and overweight. Postepy Hig Med Dosw. 2017; 71: 761–772.Owczarczyk-SaczonekAPlacekWCompounds of psoriasis with obesity and overweightPostepy Hig Med Dosw20177176177210.5604/01.3001.0010.385428894050Search in Google Scholar
Budu-Aggrey A, Brumpton B, Tyrrell J, Watkins S, Modalsli EH, Celis-Morales C, Ferguson LD, Vie GA, Palmer T, Fritsche LG, et al. Evidence of a causal relationship between body mass index and psoriasis: A Mendelian randomization study. PLoS Med. 2019; 16: e1002739.Budu-AggreyABrumptonBTyrrellJWatkinsSModalsliEHCelis-MoralesCFergusonLDVieGAPalmerTFritscheLGEvidence of a causal relationship between body mass index and psoriasis: A Mendelian randomization studyPLoS Med201916e100273910.1371/journal.pmed.1002739635495930703100Search in Google Scholar
Mahil SK, McSweeney SM, Kloczko E, McGowan B, Barker JN, Smith CH. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic. Br J Dermatol. 2019; 181: 946–953.MahilSKMcSweeneySMKloczkoEMcGowanBBarkerJNSmithCHDoes weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topicBr J Dermatol201918194695310.1111/bjd.1774130729517Search in Google Scholar
Jin Y, Zhang F, Yang S, Kong Y, Xiao F, Hou Y, Fan X, Zhang X. Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci. 2008; 52: 123–129.JinYZhangFYangSKongYXiaoFHouYFanXZhangXCombined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han populationJ Dermatol Sci20085212312910.1016/j.jdermsci.2008.04.01618585007Search in Google Scholar
Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, Margolis DJ, Gelfand JM. Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom. J Invest Dermatol. 2012; 132: 556–562.LanganSMSeminaraNMShinDBTroxelABKimmelSEMehtaNNMargolisDJGelfandJMPrevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United KingdomJ Invest Dermatol201213255656210.1038/jid.2011.365327849922113483Search in Google Scholar
Wong Y, Nakamizo S, Tan KJ, Kabashima K. An update on the role of adipose tissues in psoriasis. Front Immunol. 2019; 10: 1507.WongYNakamizoSTanKJKabashimaKAn update on the role of adipose tissues in psoriasisFront Immunol201910150710.3389/fimmu.2019.01507660987331316526Search in Google Scholar
Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, Beguinot F, Miele C. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci. 2019; 20: 2358.LongoMZatteraleFNaderiJParrilloLFormisanoPRacitiGABeguinotFMieleCAdipose tissue dysfunction as determinant of obesity-associated metabolic complicationsInt J Mol Sci201920235810.3390/ijms20092358653907031085992Search in Google Scholar
Vega-Robledo GB, Rico-Rosillo MG. Adipose tissue: Immune function and alterations caused by obesity. Rev Alerg Mex. 2019; 66: 340–353.Vega-RobledoGBRico-RosilloMGAdipose tissue: Immune function and alterations caused by obesityRev Alerg Mex201966340353Search in Google Scholar
Carrascosa JM, Rocamora V, Fernandez-Torres RM, Jimenez-Puya R, Moreno JC, Coll-Puigserver N, Fonseca E. Obesity and psoriasis: Inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermo-Sifiliográficas (English Ed.). 2014; 105: 31–44.CarrascosaJMRocamoraVFernandez-TorresRMJimenez-PuyaRMorenoJCColl-PuigserverNFonsecaEObesity and psoriasis: Inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implicationsActas Dermo-Sifiliográficas (English Ed.)2014105314410.1016/j.adengl.2012.08.024Search in Google Scholar
Boehncke WH, Boehncke S, Tobin AM, Kirby B. The “psoriatic march:” A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20: 303–307.BoehnckeWHBoehnckeSTobinAMKirbyBThe “psoriatic march:” A concept of how severe psoriasis may drive cardiovascular comorbidityExp Dermatol20112030330710.1111/j.1600-0625.2011.01261.x21410760Search in Google Scholar
Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, Collins N, Dzutsev A, Shaik J, Morais da Fonseca D, Harrison OJ, Tamoutounour S, Byrd AL, et al. White adipose tissue is a reservoir for memory T cells and promotes protective memory responses to infection. Immunity. 2017; 47: 1154–1168.HanSJGlatman ZaretskyAAndrade-OliveiraVCollinsNDzutsevAShaikJMorais da FonsecaDHarrisonOJTamoutounourSByrdALWhite adipose tissue is a reservoir for memory T cells and promotes protective memory responses to infectionImmunity2017471154116810.1016/j.immuni.2017.11.009577306829221731Search in Google Scholar
Saczonek A, Krajewska-Włodarczyk M, Kasprowicz-Furmańczyk M, Placek W. Immunological memory of psoriatic lesions. Int J Mol Sci. 2020; 21: 625.SaczonekAKrajewska-WłodarczykMKasprowicz-FurmańczykMPlacekWImmunological memory of psoriatic lesionsInt J Mol Sci20202162510.3390/ijms21020625701414831963581Search in Google Scholar
Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007; 449: 564–569.LandeRGregorioJFacchinettiVChatterjeeBWangYHHomeyBCaoWWangYHSuBNestleFOPlasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptideNature200744956456910.1038/nature0611617873860Search in Google Scholar
Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: An antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012; 24: 126–135.ReinholzMRuzickaTSchauberJCathelicidin LL-37: An antimicrobial peptide with a role in inflammatory skin diseaseAnn Dermatol20122412613510.5021/ad.2012.24.2.126334690122577261Search in Google Scholar
Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Caggese E, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis: Evidence from the Psocare project. Dermatology. 2008; 217: 365–373.NaldiLAddisAChimentiSGiannettiAPicardoMTominoCMaccaroneMChatenoudLBertuccioPCaggeseEImpact of body mass index and obesity on clinical response to systemic treatment for psoriasis: Evidence from the Psocare projectDermatology200821736537310.1159/00015659918810241Search in Google Scholar
Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Gruvald EL, Curtis JR, Sandborn WJ. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018; 13: e0195123.SinghSFacciorussoASinghAGVande CasteeleNZarrinparAProkopLJGruvaldELCurtisJRSandbornWJObesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysisPLoS One201813e019512310.1371/journal.pone.0195123595739529771924Search in Google Scholar
Driessen RJB, Boezeman JB, Van De Kerkhof PCM, De Jong EMGJ. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. Dermatolog Treat. 2009; 20: 42–47.DriessenRJBBoezemanJBVan De KerkhofPCMDe JongEMGJCardiovascular risk factors in high-need psoriasis patients and its implications for biological therapiesDermatolog Treat200920424710.1080/0954663080222570218649164Search in Google Scholar
Hossler EW, Wood GC, Still CD, Mowad CM, Maroon MS. The effect of weight loss surgery on the severity of psoriasis. Br J Dermatol. 2013; 168: 660–661.HosslerEWWoodGCStillCDMowadCMMaroonMSThe effect of weight loss surgery on the severity of psoriasisBr J Dermatol201316866066110.1111/j.1365-2133.2012.11211.x489674122880618Search in Google Scholar
Egeberg A, Sørensen JA, Gislason GH, Knop FK, Skov L. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery. JAMA Surg. 2017; 152: 344–349.EgebergASørensenJAGislasonGHKnopFKSkovLIncidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgeryJAMA Surg201715234434910.1001/jamasurg.2016.461028002543Search in Google Scholar
Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012; 71: 1267–1272.LiWHanJQureshiAAObesity and risk of incident psoriatic arthritis in US womenAnn Rheum Dis2012711267127210.1136/annrheumdis-2011-201273418375422562978Search in Google Scholar
Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: An international multicenter study. J Rheumatol. 2018; 45: 378–384.EderLHarveyPChandranVRosenCFDutzJElderJTRahmanPRitchlinCTRohekarSHaydayRGaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: An international multicenter studyJ Rheumatol20184537838410.3899/jrheum.170379584584529419462Search in Google Scholar
Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015; 74: 813–817.EderLThavaneswaranAChandranVCookRJGladmanDDObesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritisAnn Rheum Dis20157481381710.1136/annrheumdis-2013-20444824431392Search in Google Scholar
Galíndez E, Carmona L. Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug? Reumatol Clínica (English Ed.). 2016; 12: 307–312.GalíndezECarmonaLIs obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug?Reumatol Clínica (English Ed.)20161230731210.1016/j.reumae.2015.12.002Search in Google Scholar
Haroon M, Gallagher P, Heffernan E, FitzGerald O. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014; 41: 1357–1365.HaroonMGallagherPHeffernanEFitzGeraldOHigh prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying diseaseJ Rheumatol2014411357136510.3899/jrheum.14002124931949Search in Google Scholar
Klingberg E, Bilberg A, Björkman S, Hedberg M, Jacobsson L, Forsblad-d’Elia H, Carlsten H, Eliasson B, Larsson I. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: An interventional study. Arthritis Res Ther. 2019; 21: 17.KlingbergEBilbergABjörkmanSHedbergMJacobssonLForsblad-d’EliaHCarlstenHEliassonBLarssonIWeight loss improves disease activity in patients with psoriatic arthritis and obesity: An interventional studyArthritis Res Ther2019211710.1186/s13075-019-1810-5633046330635024Search in Google Scholar
Minno MND, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014; 73: 1157–1162.MinnoMNDPelusoRIervolinoSRussolilloALupoliRScarpaRWeight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockersAnn Rheum Dis2014731157116210.1136/annrheumdis-2012-202812403311423771989Search in Google Scholar
Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64: 1150–1157.AntoniCKruegerGGde VlamKBirbaraCBeutlerAGuzzoCZhouBDooleyLTKavanaughAIMPACT 2 Trial InvestigatorsInfliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trialAnn Rheum Dis2005641150115710.1136/ard.2004.032268175560915677701Search in Google Scholar
Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–2272.MeasePJKivitzAJBurchFXSiegelELCohenSBOryPSalonenDRubensteinJSharpJTTsujiWEtanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis Rheum2004502264227210.1002/art.2033515248226Search in Google Scholar
McGonagle DG, Helliwell P, Veale D. Enthesitis in psoriatic disease. Dermatology. 2012; 225: 100–109.McGonagleDGHelliwellPVealeDEnthesitis in psoriatic diseaseDermatology201222510010910.1159/00034153623108016Search in Google Scholar
Kruglikov I, Wollina U. Local effects of adipose tissue in psoriasis and psoriatic arthritis. Psoriasis Targets Ther. 2017; 7: 17–25.KruglikovIWollinaULocal effects of adipose tissue in psoriasis and psoriatic arthritisPsoriasis Targets Ther20177172510.2147/PTT.S122959577460029387604Search in Google Scholar
Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019; 20: 863–872.ChiricozziAGisondiPGirolomoniGThe pharmacological management of patients with comorbid psoriasis and obesityExpert Opin Pharmacother20192086387210.1080/14656566.2019.158320730794469Search in Google Scholar
Gisondi P, Bellinato F, Conti A, Dapavo P, Piaserico S, De Simone C, Chiricozzi A, Dattola A, Malagoli P, Malara G, et al. Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020; 34: e470–e472.GisondiPBellinatoFContiADapavoPPiasericoSDe SimoneCChiricozziADattolaAMalagoliPMalaraGConsensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasisJ Eur Acad Dermatol Venereol202034e470e47210.1111/jdv.1638032189348Search in Google Scholar
Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol. 2014; 70: 168–177.HughJVan VoorheesASNijhawanRIBagelJLebwohlMBlauveltAHsuSWeinbergJMFrom the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapiesJ Am Acad Dermatol20147016817710.1016/j.jaad.2013.09.02024184141Search in Google Scholar
Maza A, Montaudié H, Sbidian E, Gallini A, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, et al. Oral cyclosporin in psoriasis: A systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011; 25: 19–27.MazaAMontaudiéHSbidianEGalliniAAractingiSAubinFBachelezHCribierBJolyPJullienDOral cyclosporin in psoriasis: A systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasisJ Eur Acad Dermatol Venereol201125192710.1111/j.1468-3083.2011.03992.x21388455Search in Google Scholar
Bardazzi F, Odorici G, Magnano M, Patrizi A, Tengattini V. Cyclosporine in clinical practice: A retrospective study comparing fixed dose and body weight-based dose regimens in psoriatic patients. G Ital Dermatol Venereol. 2018; 155: 146–149.BardazziFOdoriciGMagnanoMPatriziATengattiniVCyclosporine in clinical practice: A retrospective study comparing fixed dose and body weight-based dose regimens in psoriatic patientsG Ital Dermatol Venereol201815514614910.23736/S0392-0488.18.05651-129368846Search in Google Scholar
Thaçi D, Bräutigam M, Kaufmann R, Weidinger G, Paul C, Christophers E. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology. 2002; 205: 383–388.ThaçiDBräutigamMKaufmannRWeidingerGPaulCChristophersEBody-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised studyDermatology200220538338810.1159/00006642512444336Search in Google Scholar
Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: A randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008; 88: 1242–1247.GisondiPDel GiglioMDi FrancescoVZamboniMGirolomoniGWeight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: A randomized, controlled, investigator-blinded clinical trialAm J Clin Nutr20088812421247Search in Google Scholar
Corbetta S, Angioni R, Cattaneo A, Becke-Peccoz P, Spada A. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol. 2006; 154: 83–86.CorbettaSAngioniRCattaneoABecke-PeccozPSpadaAEffects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokinesEur J Endocrinol2006154838610.1530/eje.1.0205716381995Search in Google Scholar
Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008; 58: 443–446.ClarkLLebwohlMThe effect of weight on the efficacy of biologic therapy in patients with psoriasisJ Am Acad Dermatol20085844344610.1016/j.jaad.2007.11.01118083274Search in Google Scholar
Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira HD. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2014; 13: 554–562.NavariniAAPoulinYMenterAGuYTeixeiraHDAnalysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasisJ Drugs Dermatol201413554562Search in Google Scholar
Di Lernia V, Tasin L, Pellicano R, Zumiani G, Albertini G. Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat. 2012; 23: 404–409.Di LerniaVTasinLPellicanoRZumianiGAlbertiniGImpact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasisJ Dermatolog Treat20122340440910.3109/09546634.2011.59348921781016Search in Google Scholar
Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A, Chimenti S. Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis. Pharmacol Res. 2008; 57: 290–295.SaracenoRSchipaniCMazzottaAEspositoMDi RenzoLDe LorenzoAChimentiSEffect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasisPharmacol Res20085729029510.1016/j.phrs.2008.02.00618400510Search in Google Scholar
Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity? Expert Opin Pharmacother. 2019; 20: 1303–1308.DalamagaMPapadavidECan we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity?Expert Opin Pharmacother2019201303130810.1080/14656566.2019.160329431002541Search in Google Scholar
Gisondi P, Girolomoni G. Impact of TNF-α antagonists on the quality of life in selected skin diseases. G Ital Dermatologia Venereol. 2013; 148: 243–248.GisondiPGirolomoniGImpact of TNF-α antagonists on the quality of life in selected skin diseasesG Ital Dermatologia Venereol2013148243248Search in Google Scholar
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, et al. Secukinumab in plaque psoriasis: Results of two phase 3 trials. N Engl J Med. 2014; 371: 326–338.LangleyRGElewskiBELebwohlMReichKGriffithsCEMPappKPuigLNakagawaHSpelmanLSigurgeirssonBSecukinumab in plaque psoriasis: Results of two phase 3 trialsN Engl J Med201437132633810.1056/NEJMoa131425825007392Search in Google Scholar
Hegazy S, Konstantinou MP, Bulai Livideanu C, Tauber M, Paul C. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. J Eur Acad Dermatol Venereol. 2019; 33: e338–e341.HegazySKonstantinouMPBulai LivideanuCTauberMPaulCEfficacy of ixekizumab in patients with resistance or incomplete response to secukinumabJ Eur Acad Dermatol Venereol201933e338e34110.1111/jdv.1563031001858Search in Google Scholar
Magdaleno-Tapial J, Carmena-Ramón R, Valenzuela-Oñate C, Ortiz-Salvador JM, Sabater-Abad J, Hernandez-Bel P, Gimeno-Carpio E, Sanchez-Carazo JL, Perez-Ferriols A. Efficacy and safety of ixekizumab in a real-life practice: A retrospective bicentric study. Actas Dermosifiliogr. 2019; 110: 585–589.Magdaleno-TapialJCarmena-RamónRValenzuela-OñateCOrtiz-SalvadorJMSabater-AbadJHernandez-BelPGimeno-CarpioESanchez-CarazoJLPerez-FerriolsAEfficacy and safety of ixekizumab in a real-life practice: A retrospective bicentric studyActas Dermosifiliogr201911058558910.1016/j.adengl.2019.06.004Search in Google Scholar
Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter A. Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2020; 82: 519–522.LebwohlMGLeonardiCLMehtaNNGottliebABMendelsohnAMParnoJRozzoSJMenterATildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)J Am Acad Dermatol20208251952210.1016/j.jaad.2019.09.04231563641Search in Google Scholar
Ruiz-Villaverde R, Ayén-Rodriguez A, Llamas-Molina JM, Ruiz-Carrascosa JC. Risankizumab as a promising therapeutic approach in obese patients. Dermatol Ther. 2020; 33: e13323.Ruiz-VillaverdeRAyén-RodriguezALlamas-MolinaJMRuiz-CarrascosaJCRisankizumab as a promising therapeutic approach in obese patientsDermatol Ther202033e1332310.1111/dth.1332332196833Search in Google Scholar
Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018; 178: 132–139.GordonKBBlauveltAFoleyPSongMWasfiYRandazzoBShenYKYouYGriffithsCEMEfficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studiesBr J Dermatol201817813213910.1111/bjd.1600828940259Search in Google Scholar
Torres T, Puig L. Apremilast: A novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin. 2018; 19: 23–32.TorresTPuigLApremilast: A novel oral treatment for psoriasis and psoriatic arthritisAm J Clin201819233210.1007/s40257-017-0302-028597182Search in Google Scholar
Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther. 2016; 10: 1763–1770.GisondiPGirolomoniGApremilast in the therapy of moderate-to-severe chronic plaque psoriasisDrug Des Devel Ther2016101763177010.2147/DDDT.S108115488705327307707Search in Google Scholar
Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015; 67: 616–625.Charles-SchoemanCFleischmannRDavignonJSchwartzHTurnerSMBeysenCMiladMHellersteinMKLuoZKaplanIVPotential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinibArthritis Rheumatol20156761662510.1002/art.38974502406525470338Search in Google Scholar
Galluzzo M, D’Adamio S, Servoli S, Bianchi L, Chimenti S, Talamonti M. Tofacitinib for the treatment of psoriasis. Expert Opin Pharmacother. 2016; 17: 1421–1433.GalluzzoMD’AdamioSServoliSBianchiLChimentiSTalamontiMTofacitinib for the treatment of psoriasisExpert Opin Pharmacother2016171421143310.1080/14656566.2016.119581227267933Search in Google Scholar
Balak DMW. Fumaric acid esters in the management of psoriasis. Psoriasis Targets Ther. 2015; 5: 9–23.BalakDMWFumaric acid esters in the management of psoriasisPsoriasis Targets Ther2015592310.2147/PTT.S51490568311629387578Search in Google Scholar
Boehncke S, Fichtlscherer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S, Hardt K, Thaçi D, Boehncke WH. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: Results of a prospective longitudinal pilot trial. Arch Dermatol Res. 2011; 303: 381–388.BoehnckeSFichtlschererSSalgoRGarbaravicieneJBeschmannHDiehlSHardtKThaçiDBoehnckeWHSystemic therapy of plaque-type psoriasis ameliorates endothelial cell function: Results of a prospective longitudinal pilot trialArch Dermatol Res201130338138810.1007/s00403-010-1108-621170539Search in Google Scholar
Kim JY, Lee WJ, Lee SJ, Kim DW, Kim TH, Jun JB, Kim MB, Kim BS. An investigation on the use of complementary and alternative medicine for psoriasis. Korean J Dermatol. 2010; 48: 494–502.KimJYLeeWJLeeSJKimDWKimTHJunJBKimMBKimBSAn investigation on the use of complementary and alternative medicine for psoriasisKorean J Dermatol201048494502Search in Google Scholar
Johnson JA, Ma C, Kanada KN, Armstrong AW. Diet and nutrition in psoriasis: Analysis of the National Health and Nutrition Examination Survey (NHANES) in the United States. J Eur Acad Dermatol Venereol. 2014; 28: 327–332.JohnsonJAMaCKanadaKNArmstrongAWDiet and nutrition in psoriasis: Analysis of the National Health and Nutrition Examination Survey (NHANES) in the United StatesJ Eur Acad Dermatol Venereol20142832733210.1111/jdv.1210523432373Search in Google Scholar
Barrea L, Macchia PE, Tarantino G, Di Somma C, Pane E, Balato N, Napolitano M, Colao A, Savastano S. Nutrition: A key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. J Transl Med. 2015; 13: 303.BarreaLMacchiaPETarantinoGDi SommaCPaneEBalatoNNapolitanoMColaoASavastanoSNutrition: A key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaireJ Transl Med20151330310.1186/s12967-015-0658-y457106226376719Search in Google Scholar
Afifi L, Danesh MJ, Lee KM, Beroukhim K, Farahnik B, Ahn RS, Yan D, Singh RK, Nakamura M, Koo J, et al. Dietary behaviors in psoriasis: Patient-reported outcomes from a U.S. National Survey. Dermatol Ther. 2017; 7: 227–242.AfifiLDaneshMJLeeKMBeroukhimKFarahnikBAhnRSYanDSinghRKNakamuraMKooJDietary behaviors in psoriasis: Patient-reported outcomes from a U.S. National SurveyDermatol Ther2017722724210.1007/s13555-017-0183-4545392528526915Search in Google Scholar
Solis MY, de Melo NS, Macedo MEM, Prata Carneiro F, Sabbag CY, Lancha AH Jr, Frangella VS. Nutritional status and food intake of patients with systemic psoriasis and psoriatic arthritis associated. Einstein. 2012; 10: 44–52.SolisMYde MeloNSMacedoMEMPrata CarneiroFSabbagCYLanchaAHJrFrangellaVSNutritional status and food intake of patients with systemic psoriasis and psoriatic arthritis associatedEinstein201210445210.1590/S1679-45082012000100010Search in Google Scholar
Altunay I, Demirci GT, Ates B, Kucukunal A, Aydın C, Karamustafalıoglu O, Altuntas Y. Do eating disorders accompany metabolic syndrome in psoriasis patients? Results of a preliminary study. Clin Cosmet Investig Dermatol. 2011; 4: 139.AltunayIDemirciGTAtesBKucukunalAAydınCKaramustafalıogluOAltuntasYDo eating disorders accompany metabolic syndrome in psoriasis patients? Results of a preliminary studyClin Cosmet Investig Dermatol2011413910.2147/CCID.S24165317301521931499Search in Google Scholar
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study. Arch Dermatol. 2010; 146: 891–895.KurdSKTroxelABCrits-ChristophPGelfandJMThe risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort studyArch Dermatol2010146891895Search in Google Scholar
Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients. 2016; 8: 128.SimopoulosAPAn increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesityNutrients2016812810.3390/nu8030128480885826950145Search in Google Scholar
Upala S, Yong WC, Theparee T, Sanguankeo A. Effect of omega-3 fatty acids on disease severity in patients with psoriasis: A systematic review. Int J Rheum Dis. 2017; 20: 442–450.UpalaSYongWCThepareeTSanguankeoAEffect of omega-3 fatty acids on disease severity in patients with psoriasis: A systematic reviewInt J Rheum Dis20172044245010.1111/1756-185X.1305128261950Search in Google Scholar
Madden SK, Flanagan KL, Jones G. How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis. Clin Nutr, 2020; 39: 1026–1040.MaddenSKFlanaganKLJonesGHow lifestyle factors and their associated pathogenetic mechanisms impact psoriasisClin Nutr2020391026104010.1016/j.clnu.2019.05.00631155371Search in Google Scholar
Honda T, Kabashima K. Current understanding of the role of dietary lipids in the pathophysiology of psoriasis. J Dermatol Sci. 2019; 94: 314–320.HondaTKabashimaKCurrent understanding of the role of dietary lipids in the pathophysiology of psoriasisJ Dermatol Sci20199431432010.1016/j.jdermsci.2019.05.00331133503Search in Google Scholar
Barrea L, Balato N, Di Somma C, Macchia PE, Napolitano M, Savanelli MC, Esposito K, Colao A, Savastano S. Nutrition and psoriasis: Is there any association between the severity of the disease and adherence to the Mediterranean diet? J Transl Med. 2015; 13: 18.BarreaLBalatoNDi SommaCMacchiaPENapolitanoMSavanelliMCEspositoKColaoASavastanoSNutrition and psoriasis: Is there any association between the severity of the disease and adherence to the Mediterranean diet?J Transl Med2015131810.1186/s12967-014-0372-1431665425622660Search in Google Scholar
Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015; 15: 511–523.DennisEANorrisPCEicosanoid storm in infection and inflammationNat Rev Immunol20151551152310.1038/nri3859460686326139350Search in Google Scholar
Calder PC. Fatty acids and inflammation: The cutting edge between food and pharma. Eur J Pharmacol. 2011; 668: S50–S58.CalderPCFatty acids and inflammation: The cutting edge between food and pharmaEur J Pharmacol2011668S50S5810.1016/j.ejphar.2011.05.08521816146Search in Google Scholar
Fischer R, Konkel A, Mehling H, Blossey K, Gapelyuk A, Wessel N, von Schacky C, Dechend R, Muller DN, Rothe M, et al. Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. J Lipid Res. 2014; 55: 1150–1164.FischerRKonkelAMehlingHBlosseyKGapelyukAWesselNvon SchackyCDechendRMullerDNRotheMDietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathwayJ Lipid Res2014551150116410.1194/jlr.M047357403194624634501Search in Google Scholar
Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, Folkerts G, Friedmann PS, Frost GS, Guarner F, et al. Inflammatory disease processes and interactions with nutrition. Br J Nutr. 2009; 101: S1–S45.CalderPCAlbersRAntoineJMBlumSBourdet-SicardRFernsGAFolkertsGFriedmannPSFrostGSGuarnerFInflammatory disease processes and interactions with nutritionBr J Nutr2009101S1S4510.1017/S000711450937786719586558Search in Google Scholar
Michaëlsson G, Gerdén B, Ottosson M, Parra A, Sjöberg O, Hjelmquist G, Lööf L. Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin. Br J Dermatol. 1993; 129: 667–673.MichaëlssonGGerdénBOttossonMParraASjöbergOHjelmquistGLööfLPatients with psoriasis often have increased serum levels of IgA antibodies to gliadinBr J Dermatol199312966767310.1111/j.1365-2133.1993.tb03329.x8286249Search in Google Scholar
Infantino M, Manfredi M, Meacci F, Grossi V, Severino M, Benucci M, Bellio E, Bellio V, Nucci A, Zolfanelli F, et al. Diagnostic accuracy of anti-gliadin antibodies in Non-Celiac Gluten Sensitivity (NCGS) patients: A dual statistical approach. Clin Chim Acta, 2015; 451: 135–141.InfantinoMManfrediMMeacciFGrossiVSeverinoMBenucciMBellioEBellioVNucciAZolfanelliFDiagnostic accuracy of anti-gliadin antibodies in Non-Celiac Gluten Sensitivity (NCGS) patients: A dual statistical approachClin Chim Acta201545113514110.1016/j.cca.2015.09.01726404177Search in Google Scholar
Acharya P, Mathur M. Association between psoriasis and celiac disease: A systematic review and meta-analysis. J Am Acad Dermatol. 2020; 82: 1376–1385.AcharyaPMathurMAssociation between psoriasis and celiac disease: A systematic review and meta-analysisJ Am Acad Dermatol2020821376138510.1016/j.jaad.2019.11.03931809817Search in Google Scholar
Lin L, Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunol. 2017; 18: 1–25.LinLZhangJRole of intestinal microbiota and metabolites on gut homeostasis and human diseasesBMC Immunol20171812510.1186/s12865-016-0187-3521968928061847Search in Google Scholar
Drucker AM, Qureshi AA, Thompson JM, Li T, Cho E. Gluten intake and risk of psoriasis, psoriatic arthritis, and atopic dermatitis among United States women. J Am Acad Dermatol. 2020; 82: 661–665.DruckerAMQureshiAAThompsonJMLiTChoEGluten intake and risk of psoriasis, psoriatic arthritis, and atopic dermatitis among United States womenJ Am Acad Dermatol20208266166510.1016/j.jaad.2019.08.007700784831404570Search in Google Scholar
Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A, Green LJ, Gudjonsson JE, Koo J, Lebwohl M, et al.: Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic review. JAMA Dermatology. 2018; 154: 934–950.FordARSiegelMBagelJCordoroKMGargAGottliebAGreenLJGudjonssonJEKooJLebwohlMDietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic reviewJAMA Dermatology201815493495010.1001/jamadermatol.2018.141229926091Search in Google Scholar
Szepietowski J, Pietrzak A, Michalak-Stoma A, Chodorowska G. Lipid disturbances in psoriasis: An update. Mediators Inflamm. 2010; 2010: 535612.SzepietowskiJPietrzakAMichalak-StomaAChodorowskaGLipid disturbances in psoriasis: An updateMediators Inflamm20102010535612Search in Google Scholar
Wakkee M, Thio HB, Prens EP, Sijbrands EJG, Neumann HAM. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007; 190: 1–9.WakkeeMThioHBPrensEPSijbrandsEJGNeumannHAMUnfavorable cardiovascular risk profiles in untreated and treated psoriasis patientsAtherosclerosis20071901910.1016/j.atherosclerosis.2006.07.01116942772Search in Google Scholar
NazIroǧlu M, YIldIz K, Tamtürk B, Erturan I, Flores-Arce M. Selenium and psoriasis. Biol Trace Elem Res. 2012; 150: 3–9.NazIroǧluMYIldIzKTamtürkBErturanIFlores-ArceMSelenium and psoriasisBiol Trace Elem Res20121503910.1007/s12011-012-9479-522821504Search in Google Scholar
Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta, 2001; 303: 33–39.Rocha-PereiraPSantos-SilvaARebeloIFigueiredoAQuintanilhaATeixeiraFDislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular diseaseClin Chim Acta2001303333910.1016/S0009-8981(00)00358-2Search in Google Scholar
Kökçam I, Naziroǧlu M. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis. Clin Chim Acta, 1999; 289: 23–31.KökçamINaziroǧluMAntioxidants and lipid peroxidation status in the blood of patients with psoriasisClin Chim Acta1999289233110.1016/S0009-8981(99)00150-3Search in Google Scholar
Serwin AB, Wasowicz W, Chodynicka B. Selenium supplementation, soluble tumor necrosis factor-α receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition. 2006; 22: 860–864.SerwinABWasowiczWChodynickaBSelenium supplementation, soluble tumor necrosis factor-α receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet BNutrition20062286086410.1016/j.nut.2006.05.01116829029Search in Google Scholar
Serwin AB, Wasowicz W, Gromadzinska J, Chodynicka B. Selenium status in psoriasis and its relations to the duration and severity of the disease. Nutrition. 2003; 19: 301–304.SerwinABWasowiczWGromadzinskaJChodynickaBSelenium status in psoriasis and its relations to the duration and severity of the diseaseNutrition20031930130410.1016/S0899-9007(02)01081-XSearch in Google Scholar
Kharaeva Z, Gostova E, De Luca C, Raskovic D, Korkina L. Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition. 2009; 25: 295–302.KharaevaZGostovaEDe LucaCRaskovicDKorkinaLClinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patientsNutrition20092529530210.1016/j.nut.2008.08.01519041224Search in Google Scholar
Barrea L, Savanelli MC, Di Somma C, Napolitano M, Megna M, Colao A, Savastano S. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr Metab Disord. 2017; 18: 195–205.BarreaLSavanelliMCDi SommaCNapolitanoMMegnaMColaoASavastanoSVitamin D and its role in psoriasis: An overview of the dermatologist and nutritionistRev Endocr Metab Disord20171819520510.1007/s11154-017-9411-6548690928176237Search in Google Scholar
Lee YH, Song GG. Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: A meta-analysis. Clin Exp Dermatol. 2018; 43: 529–535.LeeYHSongGGAssociation between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: A meta-analysisClin Exp Dermatol20184352953510.1111/ced.1338129341195Search in Google Scholar
Merola JF, Han J, Li T, Qureshi AA. No association between vitamin D intake and incident psoriasis among US women. Arch Dermatol Res. 2014; 306: 305–307.MerolaJFHanJLiTQureshiAANo association between vitamin D intake and incident psoriasis among US womenArch Dermatol Res201430630530710.1007/s00403-013-1426-624232773Search in Google Scholar
Ricketts JR, Rothe MJ, Grant-Kels JM. Nutrition and psoriasis. Clin Dermatol. 2010; 28: 615–626.RickettsJRRotheMJGrant-KelsJMNutrition and psoriasisClin Dermatol20102861562610.1016/j.clindermatol.2010.03.02721034986Search in Google Scholar
Zuccotti E, Oliveri M, Girometta C, Ratto D, Di Iorio C, Occhinegro A, Rossi P. Nutritional strategies for psoriasis: Current scientific evidence in clinical trials. Eur Rev Med Pharmacol Sci. 2018; 22: 8537–8551.ZuccottiEOliveriMGiromettaCRattoDDi IorioCOcchinegroARossiPNutritional strategies for psoriasis: Current scientific evidence in clinical trialsEur Rev Med Pharmacol Sci20182285378551Search in Google Scholar
Owczarczyk-Saczonek A, Placek W. Is the diet important for psoriasis? Przegl Dermatol. 2014; 101: 319–326.Owczarczyk-SaczonekAPlacekWIs the diet important for psoriasis?Przegl Dermatol201410131932610.5114/dr.2014.45127Search in Google Scholar
Wolters M. Diet and psoriasis: Experimental data and clinical evidence. Br J Dermatol. 2005; 153: 706–714.WoltersMDiet and psoriasis: Experimental data and clinical evidenceBr J Dermatol200515370671410.1111/j.1365-2133.2005.06781.x16181450Search in Google Scholar
Hsieh EA, Chai CM, De Lumen BO, Neese RA, Hellerstein MK. Dynamics of keratinocytes in vivo using 2H2O labeling: A sensitive marker of epidermal proliferation state. J Invest Dermatol. 2004; 123: 530–536.HsiehEAChaiCMDe LumenBONeeseRAHellersteinMKDynamics of keratinocytes in vivo using 2H2O labeling: A sensitive marker of epidermal proliferation stateJ Invest Dermatol200412353053610.1111/j.0022-202X.2004.23303.x15304093Search in Google Scholar
Andersen V, Holmskov U, Bek Sørensen S, Jawhara M, Andersen KW, Bygum A, Hvid L, Grauslund J, Wied J, Glerup H, et al. A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A Danish multidisciplinary collaboration on prognostic factors and personalised medicine. Nutrients. 2017; 9: 499.AndersenVHolmskovUBek SørensenSJawharaMAndersenKWBygumAHvidLGrauslundJWiedJGlerupHA proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases: A Danish multidisciplinary collaboration on prognostic factors and personalised medicineNutrients2017949910.3390/nu9050499545222928505128Search in Google Scholar
Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial. Expert Opin Biol Ther. 2014; 14: 749–756.Al-MutairiNNourTThe effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trialExpert Opin Biol Ther20141474975610.1517/14712598.2014.90054124661040Search in Google Scholar
Jensen P, Christensen R, Zachariae C, Geiker NR, Schaadt BK, Stender S, Hansen PR, Astrup A, Skov L. Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: A prospective observational follow-up study. Am J Clin Nutr. 2016; 104: 259–265.JensenPChristensenRZachariaeCGeikerNRSchaadtBKStenderSHansenPRAstrupASkovLLong-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: A prospective observational follow-up studyAm J Clin Nutr201610425926510.3945/ajcn.115.12584927334236Search in Google Scholar
Ručević I, Perl A, Barišić-Druško V, Adam-Perl M. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol. 2003; 27: 41–48.RučevićIPerlABarišić-DruškoVAdam-PerlMThe role of the low energy diet in psoriasis vulgaris treatmentColl Antropol2003274148Search in Google Scholar
Castaldo G, Rastrelli L, Galdo G, Molettieri P, Rotondi Aufiero F, Cereda E. Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial. Nutrition. 2020; 74: 110757.CastaldoGRastrelliLGaldoGMolettieriPRotondi AufieroFCeredaEAggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trialNutrition20207411075710.1016/j.nut.2020.11075732222582Search in Google Scholar
Caso F, Navarini L, Carubbi F, Diamanti AP, Chimenti MS, Tasso M, Currado D, Ruscitti P, Ciccozzi M, Annarumma A, et al.: Mediterranean diet and psoriatic arthritis activity: A multicenter cross-sectional study. Rheumatol Int. 2020; 40: 951–958.CasoFNavariniLCarubbiFDiamantiAPChimentiMSTassoMCurradoDRuscittiPCiccozziMAnnarummaAMediterranean diet and psoriatic arthritis activity: A multicenter cross-sectional studyRheumatol Int20204095195810.1007/s00296-019-04458-731605152Search in Google Scholar
Phan C, Touvier M, Kesse-Guyot E. Adjibade M, Hercberg S, Wolkenstein P, Chosidow O, Ezzedine K, Sbidian E. Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: Results from the NutriNet-Santé cohort. JAMA Dermatology. 2018; 154: 1017–1024.PhanCTouvierMKesse-GuyotEAdjibadeMHercbergSWolkensteinPChosidowOEzzedineKSbidianEAssociation between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: Results from the NutriNet-Santé cohortJAMA Dermatology20181541017102410.1001/jamadermatol.2018.2127614302930046840Search in Google Scholar
Molina-Leyva A, Cuenca-Barrales C, Vega-Castillo JJ, Ruiz-Carrascosa JC, Ruiz-Villaverde R. Adherence to Mediterranean diet in Spanish patients with psoriasis: Cardiovascular benefits? Dermatol Ther. 2019; 32: e12810.Molina-LeyvaACuenca-BarralesCVega-CastilloJJRuiz-CarrascosaJCRuiz-VillaverdeRAdherence to Mediterranean diet in Spanish patients with psoriasis: Cardiovascular benefits?Dermatol Ther201932e1281010.1111/dth.1281030632241Search in Google Scholar
Lithell H, Bruce A, Gustafsson IB, Höglund NJ, Karlström B, Ljunghall K, Sjölin K, Venge P, Werner I, Vessby B. A fasting and vegetarian diet treatment trial on chronic inflammatory disorders. Acta Derm Venereol. 1983; 63: 397–403.LithellHBruceAGustafssonIBHöglundNJKarlströmBLjunghallKSjölinKVengePWernerIVessbyBA fasting and vegetarian diet treatment trial on chronic inflammatory disordersActa Derm Venereol198363397403Search in Google Scholar